Categories
Change Password!
Reset Password!
Pregabalin holds
significant potential in relieving post-Lichtenstein herniorrhaphy pain, but
its use in elders should be carefully monitored.
A clinical trial performed in the department of
surgery, Ayatollah Mousavi Hospital, Zanjan, Iran showed a significant
reduction in pain and opioid consumption with the use of oral pregabalin in the
first three days after herniorrhaphy.
Pregabalin, a gamma-aminobutyric acid analogue,
is used to manage conditions related to neuropathic pain, anxiety or
inflammatory problems. Mohammad Hossein Moghimi and colleagues conducted this
study to explore the significant effects of pregabalin in reducing
post-Lichtenstein herniorrhaphy pain. The trial was conducted among 60 men who
went through unilateral inguinal herniorrhaphy under spinal anaesthesia.
The patients were categorized into two groups;
one was pregabalin or investigation group, and other was a placebo or control
group. Patients in the investigation group obtained 300 mg pregabalin 2 hours
before and 150 mg oral pregabalin after 12 and 24 hours of the procedure along
with 1 mg/kg pethidine and regular postoperative medicine. Other group obtained
placebo capsules (dosage same as investigation group) along with 1 mg/kg
pethidine and regular postoperative medication. The same approach was used to
perform all surgeries. The intensity of pain was assessed in lying and walking
positions via VAS at 12 h, 24 h, 3rd and 7th day after the treatment. The
determination of adverse effects of pregabalin and pethidine intake was also
done.
Reduced VAS scores, pain and pethidine intake,
were noticed in the investigation group at 12 h, 24 h and three days after the
treatment as compared to the placebo group (p<0.05).
J Basic Clin Physiol Pharmacol
The effects of oral Pregabalin on post-Lichtenstein herniorrhaphic pain: a randomized clinical trial
Mohammad Hossein Moghimi et al.
Comments (0)